Concurrent Lower Gastrointestinal Bleeding Risk and Myocardial Ischemic Risk: Resume Aspirin or Not?
Deepak L. Bhatt,R. Hunt
DOI: https://doi.org/10.1053/j.gastro.2016.06.033
IF: 29.4
2016-08-01
Gastroenterology
Abstract:75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 Tresponse of the body is to promote clotting. This makes perfect sense if there is external injury that leads to bleeding and the response is also useful for some forms of internal “injury,” such as gastrointestinal (GI) bleeding. However, in those prone to atherosclerosis, the prothrombotic stimulus of bleeding can provoke ischemic events leading to the paradox of patients who are bleeding also being at potentially high ischemic risk. This mechanism is less likely to occur in a young healthy person, but in an older patient with established or silent atherosclerosis, myocardial ischemia may occur. Furthermore, there is a linear risk of recurrent ischemic events in patients with a history of prior ischemic events, and the antiplatelet effect of aspirin reduces this risk substantially. Withdrawal of aspirin, of course, removes this layer of antithrombotic protection. Hence, there is a rational biological basis to continue or quickly resume antiplatelet therapy in patients with recent GI bleeding, as counterintuitive as it may initially seem. In this issue of Gastroenterology, Chan et al provide provocative retrospective data that support this hypothesis. In an elegant analysis, Chan et al examined, from a single center prospective registry, a total of 295 patients on aspirin with documented lower GI bleeding. Recurrent lower GI bleeding, serious cardiovascular (CV) events (nonfatal myocardial infarction, nonfatal stroke, or death from a vascular cause), and death from other causes were assessed by an independent, blinded adjudication committee. These outcomes were compared based on cumulative duration of aspirin use during the follow-up period. The aspirin users were defined as “use during 50% of the observation period” (n 1⁄4 174), whereas nonusers were defined as “use <20% of the follow-up period” (n 1⁄4 121). The primary endpoint was overt recurrent lower GI bleeding, which was defined as a significant bleeding episode (melena or hematochezia or a drop in hemoglobin > 2 g/dL without an upper GI source or other non-GI cause of anemia being identified). Not surprisingly, over 5 years of follow-up, lower GI bleeding recurred in 18.9% of aspirin users versus 6.9% of nonusers (P 1⁄4 .007). However, serious CV events occurred in 22.8% of aspirin users versus 36.5% of nonusers (P 1⁄4 .017). Moreover, 8.2% of aspirin users died from other causes versus 26.7% of nonusers (P 1⁄4 .001). Importantly, in this observational study,